Serina Therapeutics, Inc. · AMEX:SER
Serina Therapeutics — 14th Injectables Summit (October 2024)
23 slides from Serina Therapeutics's conference presentation, Oct 2, 2024
Slide 1: SER-252 & Enable Injections enFuse: Patient-enabled Therapy for Advanced Parkinson's Disease
serina (enable therapeutics injections SER-252 (POZ-apomorphine) & Enable Injections enFuse Patient-enabled Therapy for Advanced Parkinson's Disease: A Case Study with Serina Therapeutics’ SER-252 + Enable Injections enFuse Wearable Drug Delivery Platform Randall Moreadith, MD, PhD, Matt Huddleston,
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “wo
Slide 3: POZ Platform
POZ Platform® Enabling Technology Small Molecules RNA New / improved Optimized targeting & small molecule drugs reduced immunogenicity Clinically validated Vf ADCs Improved delivery of cancer-killing toxins
Slide 4: Enable Injections
ENABLE INJECTIONS Redefining drug delivery for the benefit of patients, providers, payers, and partners vel, (@® 4o0m+ ~ (OY: * 20,000 - INJECTIONS NSA a | a “i aS 50+ (aa e r j¢ 2023 WW WY, PATENTS ae, // “7° SN LS (823) Zoe. i? 2010,
Slide 5: Enable Injections and Serina Announce Agreement to Develop SER-252 with enFuse
@ enable w injections oS rl ie Source: Enable Injections, Inc. May 15, 2024 07:30 ET Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse® for Advanced Parkinson’s Disease CINCINNATI and HUNTSVILLE, Alabama, May 15, 2024 (GLOBE NEWSWIRE) -- Enabl
Slide 6: SER-252 (POZ-Apomorphine)
SER-252 (POZ-Apomorphine) Continuous Dopaminergic Stimulation (CDS) with Best-in-class Potential for Treatment of Advanced Parkinson's Disease
Slide 7: Current Landscape for Treatment of Parkinson's Disease
Current Landscape for Treatment of Parkinson’s Disease It is not yet clear how a DM a-synuclein would be used Potential for broad role in early PD, but will still need to be combined with symptomatic therapy Z Aaroneat + New ER oral LD expected to be valuable addition to treatment paradigm, with mor
Slide 8: Treatments Approved for the Advanced Stages of Parkinson's Disease
Treatments Approved for the Advanced Stages of Parkinson's disease all Require Daily Electronic Devices and May Cause Significant Adverse Events Produodopa APO-go & Novel Infusion Products = The Vater pnp SPN-830 abtvie “Neuroderm @Supgmus Key direct future competition for SER-252 — which includes p
Slide 9: How Does POZ Accomplish Continuous Drug Delivery?
How Does POZ Accomplish Continuous Drug Delivery ? @ Drug z Cleavable Linker | Inert Pendent |< Enzymatic Drug Release ° Drug is attached to multiple pendent groups eH SHH PL Te LL Teed cme via a cleavable linker >: I e Asingle plasma enzyme © @ 6 6 6 (butyrylcholinesterase) releases the active drug
Slide 10: Chemical Structures of PD Compounds
Chemical Structures of PD Compounds Both have an accessible chemical handle ... but posed different challenges GHs HO Ke, oD oF Z m4 \_/ N Rotigotine Apomorphine * Candidate small molecules must have a “chemical handle” + Linkers are attached to the -OH (creates a stable ester), an azide moiety on t
Slide 11: Clinical Validation of POZ - SER-214 (POZ-Rotigotine) Phase 1a Trial
Clinical Validation of POZ - SER-214 (POZ-Rotigotine) Phase 1a Trial Continuous, Stable Plasma Levels of Rotigotine Safety, tolerability and PK was evaluated in 19 stably-treated Parkinson's disease patients Once-a-week injection of SER-214 vs. once-a-day Neupro™ patch SER-214 (1 mLinjection) was sa
Slide 12: Chemical Structures of PD Compounds
Chemical Structures of PD Compounds Both have an accessible chemical handle ... but posed different challenges GHs HO Ke, oD oF Z m4 \_/ N Rotigotine Apomorphine * Candidate small molecules must have a “chemical handle” + Linkers are attached to the -OH (creates a stable ester), an azide moiety on t
Slide 13: POZ-apomorphine
POZ-apomorphine The release kinetics of apomorphine required chemistry at both hydroxyl groups Normalized Released Drug Hydrolysis of POZ10p20K-Apomorphine in Human Plasma pH 7.4 at 37°C "a ° 1 _—<4t POZ10p20K [A po(Acetate )(4~ POZ10p20KIApo(-Pr POz10p20K [A po(s-Bu P.0Z10p 20K IA po(2-Methy! eteta
Slide 14: SER-252 (POZ-Apomorphine) for Advanced Parkinson's Disease
SER-252 (POZ-Apomorphine) for Advanced Parkinson's Disease Continuous delivery in the patient’s home without skin ulcers How did POZ solve the skin issues ? APO-go Infusion (12 hr) SER-252 Attachment of apomorphine to POZ is stable in the SC compartment because there is no enzyme to release it (buty
Slide 15: SER-252 (POZ-Apomorphine) for Advanced Parkinson's Disease
SER-252 (POZ-Apomorphine) for Advanced Parkinson's Disease Continuous delivery - Patients may achieve “ON” state without going into “OFF” state between doses How will POZ achieve continuous levels of apomorphine ? Predicted levels of apomorphine following an injection of SER-252 every three and a ha
Slide 16: Enable Technology Platform
ENABLE TECHNOLOGY PLATFORM 5-25 ML ENFUSE SYRINGE TRANSFER SYSTEM VIAL TRANSFER SYSTEM High Volume Delivery Original Hands-Free Hidden Needle Connected No Drug Reformulation Container Closure Flexible Delivery, Address Needle Phobia HealthCare In Clinic or at Home Dose Verification Approved in the U
Slide 17: Patient-enabled Delivery
Patient-enabled Delivery The patient can deliver SER-252 with the 25 mL enFuse® in the comfort of their home Vacuum pulls diluent into vial Attach resuspended SER-252 Once loaded the chin strap pops up Gentle rotation to dissolve SER-252 to port on Vial Transfer enFuse Adhesive is exposed when remov
Slide 18: SER-252 Development Plan
SER-252 Development Plan | ae IND-enabling Studies Phase 1 in Advanced PD Patients Phase 2b in Advanced PD Patients Interim Data Final Data serina therapeutics Design: Single Ascending Dose / Multiple Ascending Dose Primary Endpoint: o Safety and tolerability No skin irritations, no worsening of sym
Slide 19: Enable Injections - The enFuse System
Enable Injections - The enFuse® System ‘ eee How will patients receive SER-252 in the SAD Study ? How will patients deliver it in their home ? Site staff will use the syringe transfer (ST) system Patients will use the vial transfer (VT) Enable Injections Enable Injections The Phase | SAD/MAD study i
Slide 20: Market Opportunity for Advanced Parkinson's Therapies
Market Opportunity for Advanced Parkinson's Therapies US EU + UK Advanced PD prevalent patients | Advanced PD prevalent patients 150,000 J 210,000 | ~50% Not controlled 180,000 Growing 1.5% per year Major Market Patients Inadequately Controlled With Current Electronic Device Therapies 1. Parkinson's
Slide 21: POZ Apomorphine has Blockbuster Potential
POZ Apomorphine has Blockbuster Potential $1.4B to $2.2B Peak Sales Opportunity (US / EU / UK) 2,500 =*-US / EU / UK SER-252 Total Sales Upside Case =®-US / EU / UK SER-252 Total Sales Base Case 2,000 59,299 Patients = 1,500 a 3 BSS) 8 Patients 1,000 500 2032 2033 2034 2035 2036 2037 2038 2039 2040
Slide 22: Summary
Summary SER-252 + enFuse represents a disruptive new treatment for advanced Parkinson’s disease * POZ Technology ¢ Non-immunogenic polymer that is safe, provides predictable pharmacokinetics in humans ¢ SER-252 is predicted to provide continuous dopaminergic stimulation (CDS) in advanced PD without
Slide 23: Thank You
Thank You
Serina Therapeutics — 14th Injectables Summit (October 2024) on 6ix